CapitolRadar tracks every publicly disclosed ALKS trade by US congress members and corporate insiders: 2 disclosed trades (2 buys, 0 sells) by 1 tracked traders, from 2026-07-29 to 2026-09-29. Updated daily from official filings.
Want a ping when Congress buys ALKS? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Alkermes plc (ALKS) — Healthcare · Drug Manufacturers - Specialty & Generic, market cap about $6.6B.
Cluster watch: 3 distinct tracked traders disclosed buying ALKS in the last 45 days: Gilbert Cisneros, Hopkinson Craig C. (officer: EVP R&D, Chief Medical Officer), Whitaker Anne Clem (director).
CapitolRadar analysis
2 buys, 0 sells in the tracked ALKS record
Alkermes plc (ALKS), a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, recorded 2 tracked trades from July 29, 2026 through September 29, 2026. Both transactions were buys, with no sells reported in this dataset. The activity came from 1 distinct trader, so the buy count does not represent broad participation across multiple disclosed traders.
Both ALKS transactions occurred during 2026 Q3. With only 2 trades from a single person, this is a small sample. The absence of tracked sales describes only this limited period and dataset; it does not establish a longer-term trading pattern.
1 trader accounts for all disclosed activity
Gilbert Cisneros made both tracked ALKS purchases, with the latest dated September 29, 2026. Because one trader generated 100% of the recorded transactions, the activity is concentrated rather than distributed among several buyers. The supplied data includes no transaction amounts, prices or reported value ranges, so the relative size of the two purchases cannot be compared.
6 other tickers appear in the same buyer’s purchases
The ALKS buyer also purchased AORT, CSGP, HMN, PCVX, TYL and AGIO. Each overlap represents 1 of the 1 tracked ALKS buyers, reflecting the same individual in every case rather than six separate groups of buyers. These co-purchases show other disclosed buying activity but do not provide a stated reason for the ALKS transactions.
Disclosure timing is an important limitation: congressional trade reports can appear with a lag of up to 45 days, so transaction dates and public availability may differ. When transaction values are disclosed as ranges, any amount derived from those ranges is an estimate; no amount ranges were provided here. Together with the 2-trade, 1-trader sample, those constraints limit how much can be inferred from the record.
Analysis written from the tracked record on 2026-10-15; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 2 | 2 | 0 |
Who is buying ALKS?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Gilbert Cisneros | 2 | 2026-09-29 | — |
Disclosed trades in ALKS
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros | buy | $1,001 - $15,000 | — |
| 2026-07-29 | Gilbert Cisneros | buy | $15,001 - $50,000 | — |
These buyers also bought
Other stocks the tracked buyers of ALKS disclosed buying in the last six months: ATRC (1) · DCO (1) · IRT (1) · PWR (1) · WDC (1) · APG (1).
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of …
Frequently asked questions
Which politicians bought ALKS most?
Gilbert Cisneros leads with 2 disclosed buys.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.